Literature DB >> 32654852

Biologic Therapy in COVID-19.

Miguel A González-Gay1, Santos Castañeda2, Julio Ancochea3.   

Abstract

Year:  2020        PMID： 32654852      PMCID： PMC7318980          DOI： 10.1016/j.arbres.2020.06.007

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN： 0300-2896            Impact factor:   4.872


× No keyword cloud information.
  15 in total

1.  Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.

Authors:  F Diurno; F G Numis; G Porta; F Cirillo; S Maddaluno; A Ragozzino; P De Negri; C Di Gennaro; A Pagano; E Allegorico; L Bressy; G Bosso; A Ferrara; C Serra; A Montisci; M D'Amico; S Schiano Lo Morello; G Di Costanzo; A G Tucci; P Marchetti; U Di Vincenzo; I Sorrentino; A Casciotta; M Fusco; C Buonerba; M Berretta; M Ceccarelli; G Nunnari; Y Diessa; S Cicala; G Facchini
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-04       Impact factor: 3.507

2.  The Rheumatologist's Role in COVID-19.

Authors:  Randy Q Cron; W Winn Chatham
Journal:  J Rheumatol       Date:  2020-03-24       Impact factor: 4.666

Review 3.  Adult-onset Still's disease: Advances in the treatment.

Authors:  Santos Castañeda; Ricardo Blanco; Miguel A González-Gay
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-10-05       Impact factor: 4.098

Review 4.  Indications for IVIG in rheumatic diseases.

Authors:  Ben Mulhearn; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

5.  Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.

Authors:  Miguel A González-Gay; José Mayo; Santos Castañeda; José M Cifrián; José Hernández-Rodríguez
Journal:  Expert Opin Biol Ther       Date:  2020-06-04       Impact factor: 4.388

6.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

7.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.

Authors:  Peter Richardson; Ivan Griffin; Catherine Tucker; Dan Smith; Olly Oechsle; Anne Phelan; Michael Rawling; Edward Savory; Justin Stebbing
Journal:  Lancet       Date:  2020-02-04       Impact factor: 79.321

Review 8.  COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Authors:  Piercarlo Sarzi-Puttini; Valeria Giorgi; Silvia Sirotti; Daniela Marotto; Sandro Ardizzone; Giuliano Rizzardini; Spinello Antinori; Massimo Galli
Journal:  Clin Exp Rheumatol       Date:  2020-03-22       Impact factor: 4.473

Review 9.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Authors:  Yvan Jamilloux; Thomas Henry; Alexandre Belot; Sébastien Viel; Maxime Fauter; Thomas El Jammal; Thierry Walzer; Bruno François; Pascal Sève
Journal:  Autoimmun Rev       Date:  2020-05-04       Impact factor: 9.754

10.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.